Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Melanoma 6Breast Neoplasms 4Lymphoma, Non-Hodgkin 3Lymphoma 3Uveal Melanoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Renal Cell 2Carcinoma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasm Metastasis 1Mycoses 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × ProMune × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡